NCCN Guidelines Insights: Thyroid Carcinoma, Version 2.2018
Robert I. Haddad, Christian E. Nasr, Lindsay A. Bischoff et al. · Journal of the National Comprehensive Cancer Network · 2018
The NCCN Guidelines for Thyroid Carcinoma provide recommendations for the management of different types of thyroid carcinoma, including papillary, follicular, Hürthle cell, medullary, and anaplastic carcinomas. These NCCN Guidelines Insights summarize the panel discussion behind recent updates to the guidelines, including the expanding role of molecular testing for differentiated thyroid carcinoma, implications of the new pathologic diagnosis of noninvasive follicular thyroid neoplasm with papillary-like nuclear features, and the addition of a new targeted therapy option for BRAF V600E–mutated anaplastic thyroid carcinoma.
Cited by 356 works. doi:10.6004/jnccn.2018.0089
Authors
- Robert I. Haddad
- Christian E. Nasr
- Lindsay A. Bischoff
- Naifa Lamki Busaidy
- David R. Byrd
- Glenda G. Callender
- Paxton Vandiver Dickson
- Quan‐Yang Duh
- Hormoz Ehya
- Whitney Sears Goldner
- Megan R. Haymart
- Carl K. Hoh
- Jason P. Hunt
- Andrei H. Iagaru
- FOUAD R. KANDEEL
- Peter Andreas Kopp
- Dominick M. Lamonica
- Bryan McIver
- Christopher D. Raeburn
- John Andrew Ridge
References
- AJCC Cancer Staging Manual
- SEER Cancer Statistics Review, 1975-2003
- Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer
- Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer
- Thyroid incidentalomas. Prevalence by palpation and ultrasonography
- Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial
- Impact of Mutational Testing on the Diagnosis and Management of Patients with Cytologically Indeterminate Thyroid Nodules: A Prospective Analysis of 1056 FNA Samples
- American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer
- Molecular genotyping of papillary thyroid carcinoma follicular variant according to its histological subtypes (encapsulated vs infiltrative) reveals distinct BRAF and RAS mutation patterns
- Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study